Abeona Therapeutics, Inc. (ABEO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Protalix Biotherapeutics, Inc.

Eton Pharmaceuticals, Inc.

Abeona Therapeutics, Inc.

Esperion Therapeutics, Inc.

Nektar Therapeutics

ProQR Therapeutics NV

Ocugen, Inc.

Talaris Therapeutics, Inc.

Oramed Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

Reviva Pharmaceuticals Holdings, Inc.

Why is Abeona Therapeutics, Inc. ?

Poor long term growth as Operating profit has grown by an annual rate -31.06% of over the last 5 years

Flat results in Mar 26

OPERATING CASH FLOW(Y) Lowest at USD -77.72 MM
PRE-TAX PROFIT(Q) At USD -22.46 MM has Fallen at -237.9%
NET PROFIT(Q) Lowest at USD -22.46 MM

With ROE of 40.43%, it has a very attractive valuation with a 1.54 Price to Book Value

Over the past year, while the stock has generated a return of -3.83%, its profits have risen by 202.2% ; the PEG ratio of the company is 0

High Institutional Holdings at 92.4%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 2.7% over the previous quarter.

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 25.41% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -3.83% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Abeona Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Abeona Therapeutics, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Abeona Therapeutics, Inc.

-3.83%

0.58

51.02%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-10.26%

EBIT Growth (5y)

-31.06%

EBIT to Interest (avg)

-26.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.56

Sales to Capital Employed (avg)

0.13

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

92.40%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.54

EV to EBIT

-0.83

EV to EBITDA

-0.86

EV to Capital Employed

-6.58

EV to Sales

12.76

PEG Ratio

0.02

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

40.43%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -5,912% (YoY

NET SALES(9M)

Higher at USD 14.14 MM

CASH AND EQV(HY)

Highest at USD 359.67 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 3.14 times

DEBTORS TURNOVER RATIO(HY)

Highest at 3.49 times

-12What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -77.72 MM

PRE-TAX PROFIT(Q)

At USD -22.46 MM has Fallen at -237.9%

NET PROFIT(Q)

Lowest at USD -22.46 MM

Here's what is working for Abeona Therapeutics, Inc.

Net Sales

At USD 14.14 MM has Grown at inf%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Cash and Eqv

Highest at USD 359.67 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 3.14 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 3.49 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Sales

Higher at USD 14.14 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Raw Material Cost

Fallen by -5,912% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Abeona Therapeutics, Inc.

Pre-Tax Profit

At USD -22.46 MM has Fallen at -237.9%

over average net sales of the previous four periods of USD 16.29 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -22.46 MM has Fallen at -239.57%

over average net sales of the previous four periods of USD 16.09 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -77.72 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Profit

Lowest at USD -22.46 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)